Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis-Reference-Cited by-同舟云学术

Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis

Published:2013-03-05 Issue:6 Volume:27 Page:1310-1315
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Giles F J,Mauro M J,Hong F,Ortmann C-E,McNeill C,Woodman R C,Hochhaus A,le Coutre P D,Saglio G

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201369.pdf

Reference41 articles.

1. Force T, Kolaja KL . Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov 2011; 10: 111–126.

2. Cheng H, Force T . Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res 2010; 106: 21–34.

3. Kappers MH, de Beer VJ, Zhou Z, Danser AH, Sleijfer S, Duncker DJ et al. Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension 2012; 59: 151–157.

4. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011–2019.

5. Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 5204–5212.

Cited by 188 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk: A review of management strategies;Hematology, Transfusion and Cell Therapy;2024-08

2. Challenges in management of older patients with chronic myeloid leukemia;Leukemia & Lymphoma;2024-04-23

3. Nilotinib-induced alterations in endothelial cell function recapitulate clinical vascular phenotypes independent of ABL1;Scientific Reports;2024-03-26

4. Arterio-occlusive events among patients with chronic myeloid leukemia on tyrosine kinase inhibitors;Blood;2024-03-07

5. BCR/ABL-Positive Chronic Myeloid Leukemia in Children: Current Treatment Approach;Current Oncology Reports;2024-02-10